Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer's $1.1 Bil. Chiron Diagnostics Buy Adds Blood Gas Analyzer Line

This article was originally published in The Gray Sheet

Executive Summary

Acquisition of Chiron Diagnostics for $1.1 bil. provides Bayer with an entry into the blood gas analysis market, broadens clinical laboratory systems offerings and will accelerate development efforts in the field of nucleic acid diagnostics.

You may also be interested in...



Versant HIV-1 Assay Approval Could Cut Lab Labor In Half – Bayer

Bayer Diagnostics' Versant HIV-1 RNA 3.0 assay is the first viral load test approved by FDA that can detect any clinically significant change in HIV-1 in one test-run, the company claims

Versant HIV-1 Assay Approval Could Cut Lab Labor In Half – Bayer

Bayer Diagnostics' Versant HIV-1 RNA 3.0 assay is the first viral load test approved by FDA that can detect any clinically significant change in HIV-1 in one test-run, the company claims

Bayer Bolsters Nucleic Acid Diagnostics Portfolio With VGI Acquisition

Bayer Diagnostics will gain the only FDA-approved HIV sequencing resistance test available in the U.S. through its roughly $60 mil. cash acquisition of Visible Genetics, Inc

Related Content

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel